[Hypertension trials--for whom?].
作者信息
Hjelmqvist Bengt
机构信息
Nybro vård-central, Sweden.
出版信息
Lakartidningen. 2005;102(47):3587; discussion 3588-9.
PMID:16408397
Abstract
摘要
相似文献
1
[Hypertension trials--for whom?].
Lakartidningen. 2005;102(47):3587; discussion 3588-9.
2
[Tax payers have payed billions for the "blood pressure maffia's" actions].
Lakartidningen. 2003 May 22;100(21):1917-8.
3
[ALLHAT--epoch-making?].[抗高血压和降脂治疗预防心脏病发作试验（ALLHAT）——具有划时代意义？]
Ugeskr Laeger. 2005 Sep 5;167(36):3422; author reply 3422-3.
4
Unease on industry's role in hypertension debate.对该行业在高血压辩论中所扮演角色的不安。
N Y Times Web. 2006 May 20:A1, C9.
5
6
Hypertension control: improved, but not enough!
Am J Hypertens. 2007 Apr;20(4):347. doi: 10.1016/j.amjhyper.2007.02.002.
7
Hypertension hype.高血压炒作。
Time. 2002;160(27):158.
8
[The Swedish Society of Hypertension: cooperation with industry is desirable and necessary--with integrity preserved].[瑞典高血压学会：与行业合作是可取且必要的——同时保持诚信]
Lakartidningen. 2003 May 22;100(21):1919-20.
9
[Innovation or pseudo-innovation: that is the question].[创新还是伪创新：这就是问题所在]
Med Klin (Munich). 2006 Mar 15;101(3):257-62. doi: 10.1007/s00063-006-1034-8.
10
Discrepancies between use of antihypertensive drugs and guidelines indications: pharmacoeconomic implications.抗高血压药物使用与指南适应症之间的差异：药物经济学影响。
J Hum Hypertens. 2005 Oct;19(10):819-22. doi: 10.1038/sj.jhh.1001900.
Zotero 插件